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AbstrACt
Purpose The LipidCardio Study was established for in-
depth analyses of cardiovascular risk factors, providing 
well-defined cardiovascular and metabolic phenotypes. 
In particular, the role of lipoproteins in the pathobiological 
process and treatment of cardiovascular disease (CVD) will 
be a main focus.
Participants 1005 individuals aged 21 years and older 
undergoing cardiac catheterisation during 17 months 
at a tertiary academic cardiology centre were enrolled 
(troponin-positive acute coronary syndrome was exclusion 
criterion). The baseline data not only contain detailed 
phenotyping, broad biochemical parameters, genetic 
data, but also standardised personal and family history, 
a screening test for cognitive impairment, pulse wave 
analysis and measurements of hand grip strength, among 
others. Blood samples were stored in a biobank for future 
analyses.
Findings to date The mean age of the participants at 
enrolment was 70.9±11.1 years (70% male). Coronary 
angiography provided evidence of obstructive coronary 
artery disease (CAD) in 69.9% of participants. Those with 
evidence of CAD were significantly more likely to be male, 
inactive, diabetic and with a family history of CVD than 
participants without CAD.
About 20% of patients had lipoprotein(a) (Lp(a)) 
concentrations above 106.9 nmol/L (fifth quintile). These 
patients had significantly increased odds of obstructive 
CAD compared with participants in quintiles 1–4 (crude 
OR 1.70, 95% CI 1.17 to 2.48, p=0.005). There was 
reasonable evidence that with increasing severity of CAD 
the odds of having elevated Lp(a) increased. We were able 
to replicate the established strong association between 
specified single nucleotide polymorphisms (SNPs) in the 
LPA gene (rs10455872, rs3798220 and rs186696265) and 
the APOE gene (rs7412), and the concentration of Lp(a), 
validating our phenotype database and biobank.
Future plans Mortality information will be obtained 
in 2 year intervals. Follow-up phone interviews will be 
conducted at 3 and 6 years after enrolment. We seek to 
cooperate with other researchers, for example, by sharing 
data and biobank samples.
IntroduCtIon
Ischaemic heart disease accounts for >20% of 
all deaths in Europe.1 Although age-adjusted 
mortality rates from coronary artery disease 
(CAD) have declined substantially in the past 
decades throughout Europe and the USA, 
the CAD burden remains high.1–3
Traditional modifiable risk factors for CAD 
perform well in predicting the risk of devel-
oping CAD and targeting them decreases 
cardiovascular risk in a dose-dependent 
manner.4
Still, about half of patients with prevalent 
CAD remain at very high residual risk of recur-
rent events despite optimally controlled risk 
factors.5 Identification of additional modifi-
able risk factors to reduce—residual—cardio-
vascular risk is essential. Novel biomarkers 
and assessment of the individual genetic 
profile bear the potential of improving risk 
assessment and management in both primary 
and secondary prevention.
In this regard, lipoprotein(a) (Lp(a)) has 
emerged as a novel independent risk factor 
for CAD.6 Lp(a), whose serum level is largely 
genetically determined, is still a subject of 
controversy.6 7 For example, the underlying 
strengths and limitations of this study
 ► This cohort has up-to-date coronary angiograph-
ic information on all included subjects. While the 
majority of participants has confirmed obstructive 
coronary artery disease (CAD), there is a sufficiently 
large internal comparison group which is evidential-
ly free from any detectable CAD.
 ► In addition, we are able to differentiate a group with 
non-obstructive CAD, constituting an interesting 
intermediate group. This differentiation is partic-
ularly important in terms of working with distinct 
phenotypes.
 ► In addition to comprehensive clinical information, 
we assessed functional status, lifestyle factors and 
genetics.
 ► A high quality biobank was established.
 ► A potential weakness is that patients were only re-
cruited from one tertiary care hospital. Therefore, 
the results may not be readily generalised to other 
patients with CAD.
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physiological function of this lipoprotein is still unknown. 
There is reasonable evidence that Lp(a) is causally associ-
ated with CAD,8 positively associated with coronary lesion 
severity and an independent risk factor for major adverse 
cardiovascular events, that is, the progression of CAD in 
patients with stable CAD who received optimal medical 
therapy.7 9
Screening for elevated Lp(a) presently is recommended 
in those at intermediate or high CV risk, in particular as 
an additional risk indicator.7 10 11 To note, Lp(a) has also 
been suggested as a potential therapeutic target,12 and 
an antisense oligonucleotide specific to apolipoprotein 
(a) has been recently shown to lead to dose-dependent 
reductions in average Lp(a) levels of >80%.13
Obviously, patients with prevalent CAD are a very 
heterogeneous group. Therefore, discrimination is likely 
to be advantageous over a one fits all disease management 
strategy. Further improvements in the management of 
CAD will presuppose careful characterisation of different 
phenotypes and subsequent joint application of genetics, 
epigenetics and metabolomics. For this purpose, we estab-
lished the LipidCardio Study in 2016. We sought to imple-
ment detailed phenotyping and follow-up of patients with 
different severity of CAD and also without obstructive 
CAD to examine factors associated with the pathophysio-
logical process and progression of cardiovascular disease 
(CVD). There will be a strong focus on lipoproteins and 
genetics. In particular, we seek to gain further insight into 
the role of Lp(a) in cardiovascular pathogenesis and to 
investigate the implications of a screening for Lp(a) in a 
high risk cohort of patients undergoing coronary angiog-
raphy. Combining phenotype factors with genetic factors, 
we desire to elaborate the particular cardiovascular risk 
profile of patients with high Lp(a).
As another integral part of this study, we have collected 
ample blood specimens to hold high-quality, well-charac-
terised biomaterials along with their clinical, genetic and 
demographic information for future biomedical research 
projects in store in a high-quality biobank.
Cohort description
Patients aged 18 years and older undergoing cardiac cath-
eterisation at a single large academic centre (Department 
of Cardiology, Campus Benjamin Franklin, Charité-Uni-
versitätsmedizin Berlin), except those with troponin-pos-
itive acute coronary syndromes (ACS), were eligible for 
inclusion. Participation rate was particularly high (>95%). 
Between October 2016 and March 2018, 1005 consecu-
tive patients were enrolled. All participants gave written 
informed consent at the time of enrolment. Patients 
unable to provide informed consent were excluded from 
the study.
The main study variables are shown in online supple-
mentary table 1. A comprehensive data collection was 
performed, with a strong focus on cardiovascular health. 
Blood specimens were collected at the time of cardiac 
catheterisation (after administration of heparin), either 
as arterial blood sample directly from the radial or 
femoral artery sheath or as a venous blood sample from 
peripheral intravenous access. At enrolment, patients 
were interviewed to collect information on demographic 
characteristics, over-the-counter medication usage, 
health behaviours (alcohol/drug use, smoking and 
physical activity), a detailed standardised family history 
was obtained, and a screening test for cognitive impair-
ment, the mini-mental state examination (MMSE), was 
performed. Information on regular prescription medica-
tions were obtained from the patients’ medication plan. 
In addition, electronic medical records were reviewed by 
study personnel to obtain previous diagnoses of chronic 
conditions, as well as to document previous angiographic 
findings and coronary revascularisation history.
Specimens
Portions of the blood specimens were used to deter-
mine a basic panel of laboratory tests essential to this 
study. Lp(a) was determined using a turbidimetric assay 
(Roche Diagnostics GmbH, Mannheim). Lp(a) is given in 
nmol/L, correctly reflecting the number of Lp(a) parti-
cles.14 A range of other parameters were taken over from 
the hospital information system, provided that they were 
ordered as part of the clinical routine. Importantly, all 
tests were done in one central, accredited laboratory.
EDTA blood samples were frozen immediately following 
collection at −80°C until DNA was isolated using the 
sbeadex livestock kit (LGC Genomics GmbH, Germany). 
Selected single nucleotide polymorphisms (SNPs) were 
genotyped using KASP chemistry (LGC, Hoddesdon, 
UK). We have also determined the two biomarkers, rela-
tive leukocyte telomere length and DNA methylation age 
(epigenetic clock), which was described elsewhere in 
detail.15
Additional blood samples were drawn and stored in the 
Central Biomaterial Bank Charité (ZeBanC),16 providing 
the opportunity for additional measurements at a later 
date.
Coronary angiography
Cardiac catheterisation and coronary angiography were 
performed according to the standard protocols of the 
Interventional Cardiology Unit and by discretion of the 
interventional cardiologist. The interventional cardiolo-
gist routinely documented diagnostic findings. Compre-
hensive angiographic results at the time of enrolment 
were recorded in the study database.
Echocardiography, blood pressure measurement and pulse wave 
analysis
Echocardiography was performed as a part of the clinical 
routine and selected parameters were taken over into the 
study database.
Blood pressure was measured once on each arm, in 
a sitting position and at rest with a Boso Medicus Uno 
device with an adequate cuff size.
Central blood pressure, pulse wave reflection and pulse 
wave velocity were measured with the Mobil-O-Graph 
M









pen: first published as 10.1136/bmjopen-2019-030097 on 3 September 2019. Downloaded from 
3König M, et al. BMJ Open 2019;9:e030097. doi:10.1136/bmjopen-2019-030097
Open access
Table 1 Baseline characteristics of the LipidCardio Study, total and according to presence or absence of elevated 
lipoprotein(a) (≥107 nmol/L).
Total Lp(a)<107 nmol/L Lp(a)≥107 nmol/L
Sex, male 701 (69.8) 554 (71.5) 126 (65.3)
Age, years 70.9±11.1 70.7±11.4 71.7±9.9
Caucasian ancestry 981 (97.6) 756 (97.6) 188 (97.4)
Previous diagnosis of CAD 509 (50.7) 374 (48.3) 115 (59.6)
Previous bypass surgery 77 (7.7) 51 (6.6) 24 (12.4)
Previous myocardial infarction 310 (30.9) 227 (29.3) 61 (36.8)
Total obstructive CAD 701 (69.9) 526 (67.9) 151 (78.2)
  One vessel 156 (15.5) 122 (15.7) 27 (14.0)
  Two vessel 234 (23.3) 174 (22.5) 53 (27.5)
  Three vessel 311 (31.0) 230 (29.7) 71 (36.8)
Non-obstructive CAD 113 (11.2) 94 (12.1) 14 (7.3)
No apparent CAD 170 (16.9) 155(20) 28 (14.5)
Aortic valve stenosis 100 (12.2) 71 (11.2) 26 (16.4)
Previous stroke 98 (9.8) 71 (9.2) 24 (12.4)
Atrial fibrillation 273 (27.2) 214 (27.6) 49 (25.4)
Diabetes mellitus type 2 270 (26.9) 220 (28.4) 43 (22.3)
Hypertension 813 (81.0) 627 (80.9) 156 (80.8)
Dyslipidaemia 598 (59.6) 455 (58.7) 121 (62.7)
Cancer 181 (18.0) 136 (17.6) 42 (21.8)
PAD 91 (9.1) 64 (8.3) 23 (11.9)
CKD 164 (16.3) 121 (15.6) 35 (18.1)
COPD 109 (10.8) 87 (11.2) 17 (8.8)
LDL-C (mg/dL) 99.1±40.6 97.1±39.8 106.4±41.9
ApoA1 (g/L) 1.28±0.28 1.27±0.28 1.32±0.27
ApoB (g/L) 0.85±0.27 0.83±0.27 0.93±0.28
WC (cm) 101.7±14.1 102.1±14.4 100.6±13.6
Systolic blood pressure (mm Hg) 134.0±21.3 134.0±21.5 134.3±21.1
Statin therapy 608 (60.5) 459 (59.2) 129 (66.8)
eGFR CKD-EPI formula (mL/
min/1.73 m2)
70.0±19.7 70.4±19.7 69.2±19.6
eGFR <60 mL/min/1.73 m2 290 (29.8) 218 (29.3) 59 (30.9)
Values are mean±SD and n(%) unless stated otherwise. Of n=1005 observations values were missing in Lp(a) (n=37), LDL-C (n=41), ApoA1 
(n=50), ApoB (n=49), WC (n=153), systolic blood pressure (n=148) and eGFR (n=33).
AF, atrial fibrillation; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; CAD, coronary artery disease; CKD, chronic kidney disease; CKD-
EPI, chronic kidney disease-epidemiology collaboration; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration 
rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); PAD, peripheral arterial 
disease; WC, waist circumference.
PWA device, according to the operating instructions of 
the manufacturer.
Other measurements
Waist circumference was measured at the midpoint 
between the lower margin of the least palpable rib and 
the top of the iliac crest. Hip circumference was measured 
around the widest portion of the buttocks, with the tape 
parallel to the floor. For both measurements, the subjects 
were standing and wore little clothing.17
Hand grip strength was measured with a Smedley Dyna-
mometer (Saehan, Type SH5002).
Questionnaires
The Seattle Angina Questionnaire and the Rapid Assess-
ment of Physical Activity questionnaire were admin-
istered. Folstein’s MMSE for screening of cognitive 
impairment was administered in face-to-face interviews by 
trained study personnel.
M
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Table 2 Baseline characteristics by CAD status at baseline.
No apparent CAD Obstructive CAD Non-obstructive CAD
Prior Newly diagnosed
187 (18.6%) 509 (50.8%) 200 (19.9%) 107 (10.7%)
Age (years) 66.2±12.9 72.0±10.7 71.9±9.8 72.3±9.2
Sex (female) 107 (57.2) 95 (18.7) 58 (29.0) 42 (39.3)
Diabetes mellitus 2 38 (20.3) 157 (30.8) 52 (26.0) 23 (21.5)
Dyslipidaemia 80 (42.8) 354 (69.8) 107 (53.5) 56 (52.3)
Smoking (current) 33 (20.8) 82 (17.9) 40 (22.2) 15(15)
Smoking (former) 61 (48.4) 247 (65.7) 81 (57.9) 44 (51.8)
LDL-C (mg/dL) 115.00±37.60 85.20±35.13 117.75±44.40 104.38±37.53
HDL-C (mg/dL) 56.76±17.76 47.84±15.34 50.91±15.19 55.82±18.30
Triglycerides (mg/dL) 112 (88–156) 120 (89–174) 124 (89–185) 119 (89–158)
Lp(a) (nmol/L) 17.4 (7.2–60.3) 20.5 (5.0–99.8) 22.3 (7.2–71.4) 15.30 (5.0–44.4)
Lp(a)>106.9 nmol/L 28 (15.5) 115 (23.5) 37 (19.0) 13 (12.6)
Glucose (mg/dL) 115.0±37.3 123.1±47.1 125.7±47.7 121.9±44.6
HbA1c (%) 5.70±0.70 6.00±0.84 5.99±0.89 5.78±0.81
ApoB (g/L) 0.93±0.24 0.77±0.25 0.95±0.30 0.89±0.27
Chronic kidney disease 36 (20.3) 175 (34.9) 55 (29.1) 23 (22.3)
eGFRCKD-EPI (mL/min/1.73 m
2) 75.4±20.4 68.3±19.4 70.1±21.0 69.5±15.1
ApoA1 (g/L) 1.39±0.31 1.23±0.26 1.30±0.25 1.33±0.27
Body mass index (kg/m2) 27.89±5.05 27.83±4.70 27.58±5.03 27.75±5.40
C reactive protein (mg/L) 2.15 (1.1–9.1) 2.0 (0.9–6.9) 2.8 (1.1–7.6) 2.30 (0.8–7.0)
Systolic blood pressure (mm Hg) 131.96±20.40 133.3±21.5 138.3±20.8 132.48±20.37
Diastolic blood pressure (mm Hg) 80.6±13.0 76.5±13.8 80.5±14.1 76.1±10.9
Values are mean±SD and n(%), or median (25th–75th percentile) unless stated otherwise. Of 1003 observations, values were missing in DBP 
(n=148), SBP (n=148), CRP (n=300), BMI (n=111), ApoA1 (n=48), smoking current (n=105), smoking former (n=276), LDL-C (n=41), HDL-C 
(n=46), triglycerides (n=289), Lp(a) (n=35), glucose (n=250), HbA1c (n=22), ApoB (n=47), chronic kidney disease (n=33) and eGFRCKD-EPI (n=33).
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; CAD, coronary artery disease; CKD-EPI, chronic kidney disease-epidemiology 
collaboration; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol.
Table 3 Associations of LPA-single nucleotide polymorphisms (LPA-SNPs) and lipoprotein(a) (Lp(a)) serum levels: linear 
regression analysis on Lp(a) serum levels (log10-transformed), adjusted for age and sex
SNP Location (GRCh37.p13)
A1/A2
(call rate, %) MAF N1 β SE P value N2
rs10455872 6:160589086 A/G (99.6) 0.0736 950 0.794 0.049 5.10×10−52 933
rs3798220 6:160540105 C/T(99.9) 0.0236 953 0.865 0.092 3.93×10−20 936
rs186696265 6:160690668 C/T (99.8) 0.0170 952 0.993 0.106 7.60×10−20 935
rs429358 19:44908684 C/T(95.4) 0.1307 910 0.035 0.043 0.407 893
rs7412 19:44908822 C/T(99.9) 0.0692 953 0.150 0.057 0.008 936
A1/A2, allele 1/allele 2; Lp(a) association, genotype and Lp(a) level available; MAF, allele frequency of the minor allele in LipidCardio; N1, 
number of genotyped samples; N2, number analysed with respect to.
Planned follow-up measures
Mortality information will be obtained from the obliga-
tory registry office in 2 year intervals. Follow-up phone 
interviews will be conducted by trained study personnel, 
and the calls are planned to be made at 3 and 6 years after 
initial enrolment. Adverse CVD events, including non-fatal 
myocardial infarction, ACS, heart failure, hospitalisa-
tions, cardiac procedures (eg, revascularisation), strokes 
and peripheral arterial disease events will be recorded. 
Additional information will be collected on follow-up 
coronary angiogram data, development of comorbidi-
ties (hypertension, diabetes, cardiac arrhythmia, valvular 
M
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Figure 1 Association between single nucleotide 
polymorphism rs10455872 and lipoprotein(a) (Lp(a)) in the 
LipidCardio sample. rs10455872 genotype was significantly 
associated with median Lp(a) values (interquartile ranges 
are indicated, n=933). The p value was determined using the 
Kruskal-Wallis test.
heart disease, obstructive sleep apnoea and cancer) and 
changes in medications.
Patient and public involvement
Patients and public were not involved in the design or 




Baseline characteristics of the 1005 patients are shown in 
tables 1 and 2. The mean age at enrolment was 70.9±11.1 
years. Approximately 70% of the participants were male 
and 97.6% were of white Caucasian ancestry. Coronary 
angiography provided evidence of obstructive CAD 
(defined as >50% luminal narrowing in a major epicar-
dial vessel) in 69.9% of participants at enrolment, 11.2% 
had non-obstructive CAD and 18.8% had normal coro-
nary angiograms without evidence of atherosclerosis 
(no apparent CAD). In 509 patients (50.6%) obstruc-
tive CAD had been previously known, and angiography 
was performed for evaluation of disease progression or 
planned intervention of residual stenosis.
Those with evidence of obstructive CAD were signifi-
cantly more likely to have a positive family history of CVD 
(OR 1.48, 95% CI 1.06 to 2.06, p=0.019), compared with 
participants with no apparent CAD. Likewise, partici-
pants with obstructive CAD were significantly more likely 
to be physically inactive (OR 1.50, 95% CI 1.09 to 2.16, 
p=0.014).
Lipoprotein(a): clinical and genetic associations
The median serum concentration of Lp(a) at baseline was 
19.3 nmol/L (IQR<7.0–77.1 nmol/L). Lp(a) levels were 
positively associated with age among women, whereas in 
men Lp(a) levels were consistent across the age spectrum. 
Referring to this, whereas overall there was no evidence 
of a significant sex difference in Lp(a) levels, in patients 
aged over 60 years the median Lp(a) concentration was 
significantly higher in women (26.4; IQR 8.2–109.6) than 
in men (18.2; IQR <7.0–71.4, p=0.038).
Accounting for the right-skewed distribution of Lp(a) 
in the general population and also in cardiovascular 
high-risk populations, it has become current practice to 
examine the distribution of Lp(a) by quintiles, particu-
larly individuals in the fifth quintile being at increased 
risk of CV disease. Also, the commonly referenced 
threshold of 100–125 nmol/L (equals 50 mg/dL), usually 
corresponds approximately to the cut-off point defining 
the fifth quintile.6 18 Of total 968 patients with available 
Lp(a) measurements, 193 patients (19.9%) had Lp(a) 
values above 106.9 nmol/L (fifth quintile).
Participants in the highest quintile of Lp(a) 
(≥107 nmol/L) had significantly increased odds of 
obstructive CAD compared with participants in the lowest 
quintile (OR 1.58, 1.02 to 2.45, p=0.039) or in quintiles 
1–4 (OR 1.7, 95% CI 1.17 to 2.48, p=0.005), respec-
tively. Moreover, there was reasonable evidence that 
with increasing severity of CAD (non obstructive CAD, 
1-vessel, 2-vessel and 3-vessel obstructive CAD) the odds 
of having a significantly elevated Lp(a) increased (test for 
trend p=0.015).
Genetic associations
In order to assess if our cohort data are suitable for 
genetic association analyses, we genotyped and exam-
ined LPA-SNPs rs10455872, rs3798220 and rs186696265, 
which have been previously reported to be strongly asso-
ciated with Lp(a) serum levels.19–22 Overall, 179 patients 
(18.8%) were carriers of at least one minor allele. All 
three SNPs were significantly associated with Lp(a) 
levels in the LipidCardio cohort (table 3). The strongest 
evidence of an association with Lp(a) serum levels was 
found for rs10455872 (β=0.794; p=5.1×10−52, table 3 and 
figure 1). Our data were compatible with an overall posi-
tive association (OR 1.35; 95 % CI 0.93 to 1.99, p=0.118) 
between carrying a minor LPA variant and CAD; even 
though the evidence was week. However, when stratified 
by sex there was reasonable evidence to suggest an associ-
ation between the LPA-SNPs tested and obstructive CAD 
in women (OR 1.85, 95% CI 1.02 to 3.35, p=0.04), while 
in men there was no evidence for such an association. 
The association in women was stable even after adjusting 
for age, type 2 diabetes, LDL-C and statin therapy.
Furthermore, we genotyped the two SNPs rs429358 and 
rs7412 constituting the three isoforms of apolipoprotein 
E (APOE) apoE2, apoE3 and apoE4. Rs7412 was recently 
confirmed in a large genome-wide association meta-anal-
ysis to be associated with Lp(a) serum levels with genome 
wide significance.19 Indeed, we found rs7412 to be signifi-
cantly associated with Lp(a) concentration (β=0.15; 
p=0.008), that is, we could replicate the previous finding. 
Similar to the earlier study, there was no evidence that 
rs429358 was also associated with Lp(a) serum levels in 
M
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the LipidCardio cohort (data not shown), while there 
was reasonable evidence of an association between the 
inferred APOE isoforms (online supplementary table 2) 
and Lp(a) serum levels (β=0.015; p=0.006, n=893) (see 
online supplementary table 2).
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